Immuneel Therapeutics appoints Amit Mookim as CEO

New Delhi: Immuneel Therapeutics has named Amit Mookim as its new Chief Executive Officer. With over two decades of experience in life sciences, technology, and private equity, Mookim is set to guide Immuneel through its next growth phase, focusing on making cutting-edge immunotherapy accessible to patients across India.

Mookim joins Immuneel from IQVIA, a Fortune 500 global leader in clinical research, technology, and analytics, where he served as Managing Director for South Asia. During his tenure at IQVIA, Mookim played a key role in integrating two large organizations post-merger, overseeing the site operations of over 20,000 professionals across India. He was instrumental in driving the commercial business growth, both organically and through acquisitions.

Mookim expressed excitement about his new role: “I am very excited to be part of Immuneel’s mission towards bringing access and innovation via Cell and Gene Therapy in India. With visionary founders and an exceptional team, I am confident that we will make a meaningful impact in advancing healthcare for those who need it most.”

Before IQVIA, Mookim led KPMG India’s healthcare division, building it from the ground up. He worked with leading hospitals, private equity funds, and international healthcare companies to establish and grow their presence in India. His extensive experience in healthcare transactions, mergers and acquisitions, and private equity investments solidified his reputation as a thought leader in the industry.

Mookim has also contributed to public health initiatives in India, providing guidance to the National Health Authority on market access for startups under the Pradhan Mantri Jan Arogya Yojana (PMJAY). He has advised prominent industry organizations such as the Indian Pharmaceutical Alliance, APACMED, OPPI, FICCI, and NATHEALTH on healthcare innovation and pricing strategies. His leadership experience spans across South Asia, the Asia-Pacific, the Middle East, Sub-Saharan Africa, and Europe.

Dr. Kiran Mazumdar-Shaw, Board Director and Co-founder of Immuneel Therapeutics, expressed, “Amit’s deep understanding of the healthcare ecosystem, coupled with his strategic vision and commitment to innovation, makes him an exceptional leader for Immuneel. We are confident that under his leadership, Immuneel will continue to break new ground and make significant strides towards our goal of making life-saving therapies accessible to patients across India and beyond.”

Immuneel Therapeutics, co-founded by Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar, is committed to revolutionizing cancer treatment in India by developing innovative immune cell therapies. The company has successfully established world-class manufacturing, clinical, and regulatory capabilities and aims to expand access to transformative medicines globally.

Dr. Siddhartha Mukherjee, a Board Director and Co-founder, welcomed Mookim’s appointment: “I am thrilled with the appointment of Amit Mookim as the new CEO of Immuneel Therapeutics. His expertise aligns perfectly with Immuneel’s mission to deliver transformative immune cell therapy solutions to patients worldwide.”

Dr. Kush Parmar echoed this sentiment, “With Immuneel having successfully established world-class manufacturing, clinical, and regulatory capabilities, Amit joins us at the perfect time to lead the next phase of accelerating access to these transformative medicines via our model within India and globally.”

In his role as CEO, Mookim will focus on expanding Immuneel’s footprint across India, building partnerships with healthcare providers and public health organizations, and scaling the team to deliver innovative cell and gene therapies to patients. He will also drive global partnerships to bring innovations to India and adapt them to local needs.